These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30785074)

  • 1. Potential mechanisms of action related to the efficacy and safety of cladribine.
    Baker D; Pryce G; Herrod SS; Schmierer K
    Mult Scler Relat Disord; 2019 May; 30():176-186. PubMed ID: 30785074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
    Giovannoni G
    Neurotherapeutics; 2017 Oct; 14(4):874-887. PubMed ID: 29168160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine: mechanisms and mysteries in multiple sclerosis.
    Jacobs BM; Ammoscato F; Giovannoni G; Baker D; Schmierer K
    J Neurol Neurosurg Psychiatry; 2018 Dec; 89(12):1266-1271. PubMed ID: 29991490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K; Sipe JC
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
    Mitosek-Szewczyk K; Tabarkiewicz J; Wilczynska B; Lobejko K; Berbecki J; Nastaj M; Dworzanska E; Kolodziejczyk B; Stelmasiak Z; Rolinski J
    J Neurol Sci; 2013 Sep; 332(1-2):35-40. PubMed ID: 23835090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
    Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS.
    Moser T; Schwenker K; Seiberl M; Feige J; Akgün K; Haschke-Becher E; Ziemssen T; Sellner J
    Ann Clin Transl Neurol; 2020 Nov; 7(11):2199-2212. PubMed ID: 33002321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP; Weissert R
    Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
    Ceronie B; Jacobs BM; Baker D; Dubuisson N; Mao Z; Ammoscato F; Lock H; Longhurst HJ; Giovannoni G; Schmierer K
    J Neurol; 2018 May; 265(5):1199-1209. PubMed ID: 29550884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients - An
    Dobreanu M; Manu DR; Mănescu IB; Gabor MR; Huţanu A; Bărcuţean L; Bălaşa R
    Front Immunol; 2021; 12():743010. PubMed ID: 34970256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cladribine in the treatment of relapsing multiple sclerosis].
    Robles-Cedeno R; Ramio-Torrenta L
    Rev Neurol; 2018 Nov; 67(9):343-354. PubMed ID: 30350846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
    Meuth SG; Ruck T; Aktas O; Hartung HP
    Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development and impact of cladribine on lymphoid and myeloid cells in multiple sclerosis.
    Voo VTF; Butzkueven H; Stankovich J; O'Brien T; Monif M
    Mult Scler Relat Disord; 2021 Jul; 52():102962. PubMed ID: 33901971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of oral cladribine for the treatment of multiple sclerosis.
    Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC
    J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Cortese R; Testa G; Assogna F; De Stefano N
    CNS Drugs; 2024 Apr; 38(4):267-279. PubMed ID: 38489020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
    Sellner J; Rommer PS
    Autoimmun Rev; 2020 Apr; 19(4):102492. PubMed ID: 32062028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment.
    Kalatskaya I; Giovannoni G; Leist T; Cerra J; Boschert U; Rolfe PA
    Sci Rep; 2023 May; 13(1):8067. PubMed ID: 37202447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.